Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

L. Doherty, D. C. Gigas, S. Kesari, J. Drappatz, Ryung S. Kim, J. Zimmerman, L. Ostrowsky, P. Y. Wen

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor (EGFR) and loss of PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the mTOR (mammalian target of rapamycin) inhibitor sirolimus. The regimens were reasonably well tolerated. Nineteen percent of patients experienced a partial response and 50% had stable disease. Six-month progression-free survival for glioblastoma patients was 25%.

Original languageEnglish (US)
Pages (from-to)156-158
Number of pages3
JournalNeurology
Volume67
Issue number1
DOIs
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Sirolimus
Epidermal Growth Factor Receptor
Glioma
Glioblastoma
Tumor Suppressor Genes
Disease-Free Survival

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Doherty, L., Gigas, D. C., Kesari, S., Drappatz, J., Kim, R. S., Zimmerman, J., ... Wen, P. Y. (2006). Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology, 67(1), 156-158. https://doi.org/10.1212/01.wnl.0000223844.77636.29

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. / Doherty, L.; Gigas, D. C.; Kesari, S.; Drappatz, J.; Kim, Ryung S.; Zimmerman, J.; Ostrowsky, L.; Wen, P. Y.

In: Neurology, Vol. 67, No. 1, 07.2006, p. 156-158.

Research output: Contribution to journalArticle

Doherty, L, Gigas, DC, Kesari, S, Drappatz, J, Kim, RS, Zimmerman, J, Ostrowsky, L & Wen, PY 2006, 'Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas', Neurology, vol. 67, no. 1, pp. 156-158. https://doi.org/10.1212/01.wnl.0000223844.77636.29
Doherty, L. ; Gigas, D. C. ; Kesari, S. ; Drappatz, J. ; Kim, Ryung S. ; Zimmerman, J. ; Ostrowsky, L. ; Wen, P. Y. / Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. In: Neurology. 2006 ; Vol. 67, No. 1. pp. 156-158.
@article{aa45b9f19e7943eeb55dec5cbd23b7c3,
title = "Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas",
abstract = "Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor (EGFR) and loss of PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the mTOR (mammalian target of rapamycin) inhibitor sirolimus. The regimens were reasonably well tolerated. Nineteen percent of patients experienced a partial response and 50{\%} had stable disease. Six-month progression-free survival for glioblastoma patients was 25{\%}.",
author = "L. Doherty and Gigas, {D. C.} and S. Kesari and J. Drappatz and Kim, {Ryung S.} and J. Zimmerman and L. Ostrowsky and Wen, {P. Y.}",
year = "2006",
month = "7",
doi = "10.1212/01.wnl.0000223844.77636.29",
language = "English (US)",
volume = "67",
pages = "156--158",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

AU - Doherty, L.

AU - Gigas, D. C.

AU - Kesari, S.

AU - Drappatz, J.

AU - Kim, Ryung S.

AU - Zimmerman, J.

AU - Ostrowsky, L.

AU - Wen, P. Y.

PY - 2006/7

Y1 - 2006/7

N2 - Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor (EGFR) and loss of PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the mTOR (mammalian target of rapamycin) inhibitor sirolimus. The regimens were reasonably well tolerated. Nineteen percent of patients experienced a partial response and 50% had stable disease. Six-month progression-free survival for glioblastoma patients was 25%.

AB - Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor (EGFR) and loss of PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the mTOR (mammalian target of rapamycin) inhibitor sirolimus. The regimens were reasonably well tolerated. Nineteen percent of patients experienced a partial response and 50% had stable disease. Six-month progression-free survival for glioblastoma patients was 25%.

UR - http://www.scopus.com/inward/record.url?scp=33746807790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746807790&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000223844.77636.29

DO - 10.1212/01.wnl.0000223844.77636.29

M3 - Article

VL - 67

SP - 156

EP - 158

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 1

ER -